Inflammation and colorectal cancer.

Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer (CRC). However, the underlying mechanisms are not entirely clear. A genetic basis for the increased risk of CRC in IBD patients is only a partial explanation. It is possible that high levels of inflammatory mediators that are produced in this setting may contribute to the development and progression of CRC. Growing evidence supports a role for various cytokines, released by epithelial and immune cells, in the pathogenesis of IBD-associated neoplasia. Two key genes in the inflammatory process, cyclooxygenase-2 (COX-2) and nuclear factor kappaB (NF-kappaB), provide a mechanistic link between inflammation and cancer while other factors such as, TNF-alpha and IL-6-induced signaling have been recently shown to promote tumor growth in experimental models of colitis-associated cancer. This article reviews the pathogenesis of IBD-related CRC and summarizes the molecular mechanisms underlying the development of intestinal neoplasia in the setting of chronic inflammation.

[1]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[2]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[3]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[4]  L. Coussens,et al.  IKKα at the Crossroads of Inflammation and Metastasis , 2007, Cell.

[5]  N. Ahuja,et al.  Accelerated age-related CpG island methylation in ulcerative colitis. , 2001, Cancer research.

[6]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[7]  P. Malfertheiner,et al.  Oxidative stress in ulcerative colitis-associated carcinogenesis. , 2008, Pathology, research and practice.

[8]  N. Arber.  Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point , 2008, Cancer Epidemiology Biomarkers & Prevention.

[9]  J. Liao,et al.  Colorectal carcinoma development in inducible nitric oxide synthase‐deficient mice with dextran sulfate sodium‐induced ulcerative colitis , 2007, Molecular carcinogenesis.

[10]  P. Munkholm.  Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[11]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[12]  M. Rogy,et al.  Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. , 2001, Carcinogenesis.

[13]  S. Sommers,et al.  Cicatrizing enteritis as a pathologic entity; analysis of 120 cases. , 1948, The American journal of pathology.

[14]  F. Berger,et al.  Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Mukaida,et al.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. , 2008, The Journal of clinical investigation.

[16]  S. Grösch,et al.  Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. , 2006, Journal of the National Cancer Institute.

[17]  Y. Niv.  Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. , 2007, World journal of gastroenterology.

[18]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[19]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[20]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[21]  E. Fearon,et al.  Colitis and cancer: a tale of inflammatory cells and their cytokines. , 2008, The Journal of clinical investigation.

[22]  M. Karin.  The IκB kinase – a bridge between inflammation and cancer , 2008, Cell Research.

[23]  M. Omata,et al.  Constitutive NF-κB Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth , 2009, Clinical Cancer Research.

[24]  D. Sachar,et al.  Cancer in Crohn's disease: dispelling the myths. , 1994, Gut.

[25]  R. Hunt,et al.  Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point , 2008 .

[26]  Ming Liu,et al.  Cytokines and their relationship to the symptoms and outcome of cancer , 2010 .

[27]  M. Karin.  Inflammation and Cancer , 2008 .

[28]  S. Itzkowitz,et al.  Cancer in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[29]  B. Crohn,et al.  The sigmoidoscopic picture of chronic ulcerative colitis (non-specific) , 1925 .

[30]  Noam Harpaz,et al.  Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. , 2005, Gastroenterology.

[31]  J. K. Kundu,et al.  Inflammation: gearing the journey to cancer. , 2008, Mutation research.

[32]  W. Taylor,et al.  Crohn's disease and cancer. , 1973, The New England journal of medicine.

[33]  Xavier Matias-Guiu,et al.  NF-kB in development and progression of human cancer , 2005, Virchows Archiv.

[34]  T. Smyrk,et al.  Tumor Necrosis Factor-Alpha Polymorphisms in Ulcerative Colitis-Associated Colorectal Cancer , 2008, The American Journal of Gastroenterology.

[35]  M. Leshno,et al.  Aspirin is Clinically Effective in Chemoprevention of Colorectal Neoplasia: Point , 2008, Cancer Epidemiology Biomarkers & Prevention.

[36]  A. West,et al.  High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis. , 2006, Journal of clinical gastroenterology.

[37]  A. Karsan,et al.  Recent insights into the role of Notch signaling in tumorigenesis. , 2006, Blood.

[38]  F. Pallone,et al.  Cytokines: from gut inflammation to colorectal cancer. , 2008, Current drug targets.

[39]  J. Herman,et al.  Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. , 2000, Cancer research.

[40]  P. Lakatos,et al.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. , 2008, World journal of gastroenterology.

[41]  F. Real,et al.  Nuclear IKK activity leads to dysregulated Notch-dependent gene expression in colorectal cancer , 2007, Proceedings of the National Academy of Sciences.

[42]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.